Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14892360 | 0.94 | SIRT6 (0.89) | SIRT6MAPTLMNARECQLALDH1A1 | |
| SCHEMBL29666078 | 0.90 | SIRT6 (0.82) | SIRT6MAPTLMNARECQLALDH1A1 | |
| SCHEMBL10330200 | 0.88 | SIRT6 (0.78) | SIRT6MAPTLMNARECQLALDH1A1 | |
| SCHEMBL29666080 | 0.87 | MAPT (0.77) | SIRT6MAPTLMNARECQLALDH1A1 | |
| SCHEMBL29666087 | 0.87 | SIRT6 (0.77) | SIRT6MAPTLMNARECQLALDH1A1 | |
| SCHEMBL30059159 | 0.86 | LMNA (1.00) | SIRT6MAPTLMNARECQLALDH1A1 | |
| SCHEMBL30532598 | 0.86 | SIRT6 (0.75) | SIRT6MAPTLMNAALDH1A1MAPK1 | |
| SCHEMBL3109069 | 0.86 | LMNA (1.00) | SIRT6MAPTLMNARECQLALDH1A1 | |
| SCHEMBL27997682 | 0.86 | SIRT6 (0.75) | SIRT6MAPTLMNAALDH1A1MAPK1 | |
| SCHEMBL25877527 | 0.86 | LMNA (0.94) | SIRT6MAPTLMNARECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108997546-B | Benzoxazine resin containing carbon nitrogen and azo structure and preparation method thereof | 西南石油大学 | 2020-08-25 | — | — | CN | claimed |
| CN-108610293-B | Method for preparing dorvitinib intermediate by adopting microchannel reaction device | 南京工业大学 | 2020-08-04 | — | — | CN | claimed |
| CN-108689964-A | A kind of micro passage reaction synthesizes the method that more Weis replace Buddhist nun's intermediate | 黑龙江鑫创生物科技开发有限公司 | 2018-10-23 | — | — | CN | claimed |
| EP-1590332-B1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. | UNIV DELHI (IN) | 2011-04-27 | — | — | EP | claimed |
| EP-1590332-A1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND ITS DERIVATIONS | University of Delhi (IN) | 2005-11-02 | — | — | EP | claimed |
| WO-2004063170-A1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND ITS DERIVATIONS | UNIVERSITY OF DELHI (IN) | 2004-07-29 | — | — | WO | claimed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| CN-120535500-A | Degradation agent of target information silencing regulatory factor SIRT6 protein, and preparation method and application thereof | 深圳大学 | 2025-08-26 | — | — | CN | disclosed |
| CN-119019370-A | Degradation agent targeting SIRT6 and/or GSPT1 and application thereof | 深圳大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-119019370-A | Degradation agent targeting SIRT6 and/or GSPT1 and application thereof | 深圳大学 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024220556-A2 | HETEROCYCLIC SUMO1 SMALL MOLECULE DEGRADERS AND USE THEREOF | HB THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-118666756-A | Hydroxamic acid derivative and preparation method and application thereof | 新疆医科大学 | 2024-09-20 | — | — | CN | disclosed |
| US-6194414-B1 | CANCER THERAPY; PREVENT RADIATION DAMAGE | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 2001-02-27 | — | — | US | disclosed |
| US-6051570-A | ANTIULCER AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-04-18 | — | — | US | disclosed |
| EP-0983263-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS ANTIULCER AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998054172-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS ANTIULCER AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1998-12-03 | — | — | WO | disclosed |
| EP-0857067-A1 | RADIOPROTECTORS | The Inner and Eastern Health Care Network (AU) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997004776-A1 | RADIOPROTECTORS | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | SIRT6 3230/4885MAPT 4502/4885LMNA 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.